Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Klebsiella Pneumoniae Infections-Pipeline Review, H1 2015

Klebsiella Pneumoniae Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Klebsiella Pneumoniae Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Klebsiella Pneumoniae Infections-Pipeline Review, H1 2015', provides an overview of the Klebsiella Pneumoniae Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Klebsiella Pneumoniae Infections Overview 10

Therapeutics Development 11

Pipeline Products for Klebsiella Pneumoniae Infections-Overview 11

Pipeline Products for Klebsiella Pneumoniae Infections-Comparative Analysis 12

Klebsiella Pneumoniae Infections-Therapeutics under Development by Companies 13

Klebsiella Pneumoniae Infections-Therapeutics under Investigation by Universities/Institutes 15

Klebsiella Pneumoniae Infections-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Klebsiella Pneumoniae Infections-Products under Development by Companies 18

Klebsiella Pneumoniae Infections-Products under Investigation by Universities/Institutes 21

Klebsiella Pneumoniae Infections-Companies Involved in Therapeutics Development 22

Arsanis Biosciences GmbH 22

Cellceutix Corporation 23

Debiopharm International S.A. 24

Melinta Therapeutics, Inc 25

Merck & Co., Inc. 26

Northern Antibiotics Oy 27

Nosopharm SAS 28

Novan, Inc. 29

Pfizer Inc. 30

Phico Therapeutics Ltd. 31

Sarepta Therapeutics, Inc. 32

Shionogi & Co., Ltd. 33

Soligenix, Inc. 34

Sumitomo Dainippon Pharma Co., Ltd. 35

Syntiron LLC 36

Tetraphase Pharmaceuticals Inc. 37

Theraclone Sciences, Inc. 38

Trana Discovery, Inc. 39

Klebsiella Pneumoniae Infections-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

BXN-112-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

CB-027-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

CB-618-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

CC-1807-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CTIX-1278-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Debio-1454-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

dusquetide-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

IBN-1-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Klebsiella pneumoniae vaccine-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Monoclonal Antibodies for Klebsiella Pneumoniae Infections-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Monoclonal Antibody for Klebsiella Pneumoniae Infections-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

MVX-506-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

NAB-7061-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

NAB-739-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

NAB-741-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

NOSO-95300-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

NVN-1000-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

NVN-4428-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

PT-4-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

RX-05-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

RXP-792-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

RXP-873-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

S-649266-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

SM-295291-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

SM-369926-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecule for Gram-Negative Nosocomial Infections-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecules to Inhibit DHFR for Infectious Diseases-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

TP-076-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

TP-138-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

TP-600-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Klebsiella Pneumoniae Infections-Recent Pipeline Updates 87

Klebsiella Pneumoniae Infections-Dormant Projects 92

Klebsiella Pneumoniae Infections-Discontinued Products 93

Klebsiella Pneumoniae Infections-Product Development Milestones 94

Featured News & Press Releases 94

Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials 94

Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 94

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Tables

Number of Products under Development for Klebsiella Pneumoniae Infections, H1 2015 11

Number of Products under Development for Klebsiella Pneumoniae Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Development by Companies, H1 2015 (Contd..2) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Klebsiella Pneumoniae Infections-Pipeline by Arsanis Biosciences GmbH, H1 2015 22

Klebsiella Pneumoniae Infections-Pipeline by Cellceutix Corporation, H1 2015 23

Klebsiella Pneumoniae Infections-Pipeline by Debiopharm International S.A., H1 2015 24

Klebsiella Pneumoniae Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 25

Klebsiella Pneumoniae Infections-Pipeline by Merck & Co., Inc., H1 2015 26

Klebsiella Pneumoniae Infections-Pipeline by Northern Antibiotics Oy, H1 2015 27

Klebsiella Pneumoniae Infections-Pipeline by Nosopharm SAS, H1 2015 28

Klebsiella Pneumoniae Infections-Pipeline by Novan, Inc., H1 2015 29

Klebsiella Pneumoniae Infections-Pipeline by Pfizer Inc., H1 2015 30

Klebsiella Pneumoniae Infections-Pipeline by Phico Therapeutics Ltd., H1 2015 31

Klebsiella Pneumoniae Infections-Pipeline by Sarepta Therapeutics, Inc., H1 2015 32

Klebsiella Pneumoniae Infections-Pipeline by Shionogi & Co., Ltd., H1 2015 33

Klebsiella Pneumoniae Infections-Pipeline by Soligenix, Inc., H1 2015 34

Klebsiella Pneumoniae Infections-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 35

Klebsiella Pneumoniae Infections-Pipeline by Syntiron LLC, H1 2015 36

Klebsiella Pneumoniae Infections-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 37

Klebsiella Pneumoniae Infections-Pipeline by Theraclone Sciences, Inc., H1 2015 38

Klebsiella Pneumoniae Infections-Pipeline by Trana Discovery, Inc., H1 2015 39

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Stage and Target, H1 2015 42

Number of Products by Stage and Mechanism of Action, H1 2015 44

Number of Products by Stage and Route of Administration, H1 2015 46

Number of Products by Stage and Molecule Type, H1 2015 48

Klebsiella Pneumoniae Infections Therapeutics-Recent Pipeline Updates, H1 2015 87

Klebsiella Pneumoniae Infections-Dormant Projects, H1 2015 92

Klebsiella Pneumoniae Infections-Discontinued Products, H1 2015 93

List of Figures

Number of Products under Development for Klebsiella Pneumoniae Infections, H1 2015 11

Number of Products under Development for Klebsiella Pneumoniae Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Top 10 Targets, H1 2015 41

Number of Products by Stage and Top 10 Targets, H1 2015 42

Number of Products by Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Top 10 Routes of Administration, H1 2015 45

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46

Number of Products by Top 10 Molecule Types, H1 2015 47

Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Arsanis Biosciences GmbH

Cellceutix Corporation

Debiopharm International S.A.

Melinta Therapeutics, Inc

Merck & Co., Inc.

Northern Antibiotics Oy

Nosopharm SAS

Novan, Inc.

Pfizer Inc.

Phico Therapeutics Ltd.

Sarepta Therapeutics, Inc.

Shionogi & Co., Ltd.

Soligenix, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Syntiron LLC

Tetraphase Pharmaceuticals Inc.

Theraclone Sciences, Inc.

Trana Discovery, Inc.

Klebsiella Pneumoniae Infections Therapeutic Products under Development, Key Players in Klebsiella Pneumoniae Infections Therapeutics, Klebsiella Pneumoniae Infections Pipeline Overview, Klebsiella Pneumoniae Infections Pipeline, Klebsiella Pneumoniae Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com